A single-center observational study of reduced-dose rituximab in the treatment of ANCA-associated vasculitis
OBJECTIVE To compare the effectiveness and safety of low-dose rituximab(RTX)with cyclophosphamide(CYC)in antineutrophilcytoplasmic antibody-associated vasculitis(AAV)patients.METHODS From January 2017 to April 2023,the relevant clinical data were retrospectively reviewed for newly diagnosed and recurrent AAV patients.Based upon spe-cific treatment protocols,they were assigned into two groups of RTX(n=41)and CYC(n=81).Birmingham Vasculitis Activity Score(BVAS),glucocorticoid dosage,albumin,serum creatinine(SCr)and 24-hour proteinuria were collected for two groups at baseline and Month 3/6/12.The inter-group differences in remission rate,relapse rate and incidence of adverse drug reactions(ADR)were compared.RESULTS After treatment,no significant inter-group difference existed in remission rate at Month 6(P＞0.05).However,BVAS score and glucocorticoid dosage were lower in RTX group than those in CYC group(P＜0.05).After 12-month treatment,remission rate was higher in RTX group than that in CYC group(P＜0.05).However,relapse rate was lower in RTX group than that in CYC group(P＞0.05).Regarding safety,the incidence of hypogammaglobulinemia was higher in RTX group than that in CYC group(P＜0.05).Gastrointestinal reactions were noted in CYC group.CONCLUSION Reduced-dose RTX plus glucocorticoids may significantly alleviate disease activity,reduce glucocorticoid dose and arrest disease progression in AAV patients.
NETL
NSTL
万方数据
